NxStage System One receives FDA Approval

Posted By : Enaie Azambuja
NxStage System One receives FDA Approval

NxStage Medical has announced that the U.S. FDA has cleared its System One for solo home hemodialysis, without a care partner, during waking hours. Since receiving its first clearance for home hemodialysis from the FDA in 2005 and the first and only home nocturnal hemodialysis clearance in 2014, the NxStage System One has provided over 14 million treatments to thousands of patients in their homes around the world, during the day and at night.

However, certain patients have not had access to this therapy option due to the fact that the System One's indication has required that a care partner be present when a patient performs home hemodialysis.

This new expanded indication provides both new and existing System One patients, trained to perform solo home hemodialysis, the freedom to dialyse at home without a care partner during waking hours.

"Patients have been asking for an FDA-cleared solo option for years," stated Dr. Allan Collins, Chief Medical Officer, NxStage. "Many patients have been turned away from home hemodialysis simply because they did not have a care partner. The ability to train and treat solo provides a broader patient base with access to the clinical and quality of life benefits associated with home hemodialysis."

"We are thrilled with this milestone achievement," said Todd Snell, SVP of QA, Regulatory & Clinical Affairs, NxStage. "Our interaction with the FDA first began at a patient preference workshop followed by regular dialogue throughout the pre-submission and submission processes. The solo home hemodialysis clearance makes NxStage the first company to formally conduct a patient preference study leading to a label expansion."

"With much credit to our decade long history in the home, we continue to do amazing things for dialysis patients," said Joe Turk, President, NxStage. "As a company, we are incredibly passionate about providing patients with as much freedom and flexibility as possible to do their dialysis therapy when they want and where they want, day or night. This expanded indication for solo therapy is another significant step forward for patients."

NxStage will be working with its customers and partners to implement additional patient training for this new indication later this year and into 2018. Interested patients should talk to their nephrologist and care teams to fully understand both the risks and benefits of solo therapy to determine if solo home hemodialysis is right for them.

Downloads


You must be logged in to comment

Write a comment

No comments




More from NxStage Medical, Inc.

Sign up to view our publications

Sign up

Sign up to view our downloads

Sign up

PPMA Show 2017
26th September 2017
United Kingdom NEC, Birmingham
World’s top 50 innovators from the industries of the future
27th September 2017
United Kingdom London
New Scientist Live 2017
28th September 2017
United Kingdom Excel, London
Kiosk Summit 2017
28th September 2017
United Kingdom London
act! 2017
28th September 2017
Germany NHOW Berlin